Protein particles: What we know and what we do not know

Journal of Pharmaceutical Sciences

Volumn 101, Issue 10, 2012, Pages 3568-3579

  Ripple, Dean C ^a   Dimitrova, Mariana N ^b  

^a NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^b MEDIMMUNE   (United States)

Author keywords

Biopharmaceuticals characterization; Imaging methods; Light scattering; Microparticles; Nanoparticles; Particle size; Physical characterization; Protein aggregation

Indexed keywords

FLUORESCENT DYE; MONOCLONAL ANTIBODY; MONOMER; POLYSTYRENE; PROTEIN; SURFACTANT;

ADSORPTION KINETICS; ALGORITHM; CHEMICAL COMPOSITION; CRYOELECTRON MICROSCOPY; DEUTERIUM HYDROGEN EXCHANGE; DISSOCIATION; DRUG ADSORPTION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ELECTRON TOMOGRAPHY; FLOW CYTOMETRY; FLUORESCENCE; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFRARED SPECTROSCOPY; MECHANICAL STRESS; MICROSCOPY; OPTICAL RESOLUTION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN UNFOLDING; REVIEW; SCANNING ELECTRON MICROSCOPY; SENSITIVITY ANALYSIS;

EID: 84865378494     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23242     Document Type: Note

References (47)

1. Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, Cromwell M, Krause HJ, Mahler HC, Meyer BK, Narhi L, Nesta DP, Spitznagel T. 2010. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci 99:3302-3321.
2. Philo JS, Arakawa T. 2009. Mechanisms of protein aggregation. Curr Pharm Biotechnol 10:348-351.
3. Huang C-T, Sharma D, Oma P, Krishnamurthy R. 2009. Quantitation of protein particles in parenteral solutions using micro-flow imaging. J Pharm Sci 98:3058-3071.
4. Philo, JS. 2009. A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol 10:359-372.
5. Zölls S, Tantipolphan R, Wiggenhorn M, Winter G, Jiskoot W, Friess W, Hawe A. 2011. Particles in therapeutic protein formulations, part 1: Overview of analytical methods. J Pharm Sci 101:914-935.
6. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. 2006. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci. 95:1084-1096.
7. Rosenberg AS. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8:E501-E507.
8. Fradkin AH, Carpenter JF, Randolph TW. 2009. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 98:3247-3264.
9. Narhi LO, Schmit J, Bechtold-Peters K, Sharma D. 2012. Classification of protein aggregates. J Pharm Sci 101:493-498.
10. Bee JS, Chiu D, Sawicki S, Stevenson JL, Chatterjee K, Freund E, Carpenter JF, Randolph TW. 2009. Monoclonal antibody interactions with micro- and nanoparticles: Adsorption, aggregation, and accelerated stress studies. J Pharm Sci 98:3218-3238.
11. Bee JS, Stevenson JL, Mehta B, Svitel J, Pollastrini J, Platz R, Freund E, Carpenter JF, Randolph TW. 2009. Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol Bioeng 103:936-943.
12. Ludwig DB, Carpenter JF, Hamel JB, Randolph TW. 2010. Protein adsorption and excipient effects on kinetic stability of silicone oil emulsions. J Pharm Sci 99:1721-1733.
13. Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO. 2011. Classification and characterization of therapeutic antibody aggregates. J Biol Chem 286:25118-25133.
14. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI. 2010. High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 99:1707-1720.
15. Szymczak P, Cieplak M. 2011. Hydrodynamic effects in proteins. J Phys Condens Matter 23:033102.
16. Maa Y-F, Hsu CC. 1997. Protein denaturation by combined effect of shear and air-liquid interface. Biotechnol Bioeng 54:503-512.
17. Den Engelsman J, Garidel P, Smulders R, Mahler H-C, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W. 2011. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 28:920-933.
18. Bee JS, Randolph TW, Carpenter JF, Bishop SM, Dimitrova MN. 2011. Effects of surfaces and leachables on the stability of biopharmaceuticals. J Pharm Sci 100:4158-4170.
19. Tyagi AK, Randolph TW, Dong A, Maloney KM, Hitscherich C Jr, Carpenter JF. 2009. IgG particle formation during filling pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 98:94-104.
20. Nayak A, Colandene J, Bradford V, Perkins M. 2011. Characterization of subvisible particle formation during the filling pump operation of a monoclonal antibody solution. J Pharm Sci 100:4198-4204.
21. Kiese S, Pappenberger A, Friess W, Mahler H-C. 2010. Equilibrium studies of protein aggregates and homogeneous nucleation in protein formulation. J Pharm Sci 99:632-644.
22. Wuchner K, Büchler J, Spycher R, Dalmonte P, Volkin DB. 2010. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation. J Pharm Sci 99:3343-3361.
23. Clement CF, Wood MH. 1980. Moment and Fokker-Planck equations for the growth and decay of small objects. Proc. R Soc Lond A 371:553-567.
24. Avnir D, Farin D, Pfeifer P. 1985. Surface geometry irregularity of particulate materials: The fractal approach. J Colloid Interface Sci 103:112-123.
25. Lee C, Kramer TA. 2004. Prediction of three-dimensional fractal dimensions using the two-dimensional properties of fractal aggregates. Adv Colloid Interface Sci 112:49-57.
26. Ripple D, Wayment JR, Carrier MJ. 2010. Standards for the optical detection of protein particles. Am Pharm Rev 14:90-96.
27. Vörös J. 2004. The density and refractive index of adsorbing protein layers. Biophys J 87:553-561.
28. Sulzer B, Perelson AS. 1997. Immunons revisited: Binding of multivalent antigens to B cells. Mol Immunol 34:63-74.
29. Mant A, Chinnery F, Elliott T, Williams AP. 2012. The pathway of cross-presentation is influenced by the particle size of phagocytosed antigen. Immunology 136:163-175.
30. Lindblad EB. 2004. Aluminium compounds for use in vaccines. Immunol Cell Biol 82:497-505.
31. Hutchison S, Benson RA, Gibson VB, Pollock AH, Garside P, Brewer JM. 2012. Antigen depot is not required for alum adjuvanticity. FASEB J 26:1272-1279.
32. US Pharmacopeia. 2007. USP/NF General Chapter <788>. Particulate matter in injections. In US Pharmacopeia, National Formulary, USP31-NF-26. Rockville, Maryland: USP.
33. Jennings BR, Parslow K. 1988. Particle size measurement: The equivalent spherical diameter. Proc R S Lond A 419:137-149.
34. Cao S, Pollastrini J, Jiang Y. 2009. Separation and characterization of protein aggregates and particles by field flow fractionation. Curr Pharm Biotechnol 10:382-390.
35. Filipe V, Hawe A, Jiskoot W. 2010. Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 27:796-810.
36. Sharma DK, King D, Oma P, Merchant C. 2010. Micro-flow imaging: Flow microscopy applied to sub-visible particulate analysis in protein formulations. AAPS J 12:455-464.
37. Dai L, Coleman J, Shen D, Pande P, Patton WF. 2010. Rapid assessment of aggregates in protein-based pharmaceuticals. Poster presentation at AAPS National Biotechnology Conference, May 16-19, 2010; San Francisco, California (accessed at http://www.enzolifesciences.com/fileadmin/files/poster/ZZ_Sc0510_1012_AAPS_FINAL_A3.pdf).
38. Mach H, Bhambhani A, Meyer BK, Burek S, Davis H, Blue JT, Evans RK. 2011. The use of flow cytometry for the detection of subvisible particles in therapeutic protein formulations. J Pharm Sci 100:1671-1678.
39. Ludwig DB, Trotter JT, Gabrielson JP, Carpenter JF, Randolph TW. 2011. Flow cytometry: A promising technique for the study of silicone oil-induced particulate formation in protein formulations. Anal Biochem 410:191-199.
40. Wang L, Gaigalas AK. 2011. Development of multicolor flow cytometry calibration standards: Assignment of equivalent reference fluorophores (ERF) unit. J Res Natl Inst Stand Technol 116:671-683.
41. Demeule B, Messick S, Shire SJ, Liu J. 2010. Characterization of particles in protein solutions: Reaching the limits of current technologies. AAPS J 12:708-715.
42. Barnard JG, Rhyner MN, Carpenter JF. 2012. Critical evaluation and guidance for using the coulter method for counting subvisible particles in protein solutions. J Pharm Sci 101:140-153.
43. Filipe V, Poole R, Kutscher M, Forier K, Braeckmans K, Jiskoot W. 2011. Fluorescence single particle tracking for the characterization of submicron protein aggregates in biological fluids and complex formulations. Pharm Res 28:1112-1120.
44. Burg TP, Godin M, Shen W, Carlson G, Foster JS, Babcock K, Manalis SR. 2007. Weighing of biomolecules, single cells, and single nanoparticles in fluid. Nature 446:1066-1069.
45. Narhi LO, Jiang Y, Cao S, Benedek K, Shnek D. 2009. A critical review of analytical methods for subvisible and visible particles. Curr Pharm Biotechnol 10:373-381.
46. Li CH, Li T. 2009. Application of vibrational spectroscopy to the structural characterization of monoclonal antibody and its aggregate. Curr Pharm Biotechnol 10:391-399.
47. Zhang A, Singh SK, Shirts MR, Kumar S, Fernandez EJ. 2012. Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm Res 29:236-250.